Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.
Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, Sühs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G; Immunotherapy for PML Study Group.
Boumaza X, et al.
Ann Neurol. 2023 Feb;93(2):257-270. doi: 10.1002/ana.26512. Epub 2022 Oct 17.
Ann Neurol. 2023.
PMID: 36151879
Free PMC article.
Pembrolizumab was most commonly used (n = 53, 67.1%). One-year survival was 51.9% (41/79). PML-immune reconstitution inflammatory syndrome (IRIS) was reported in 15 of 79 patients (19%). ...Development of inflammatory features or overt PML-IRIS was com …
Pembrolizumab was most commonly used (n = 53, 67.1%). One-year survival was 51.9% (41/79). PML-immune reconstitution inflam …